Douglas Cannie

445 total citations
13 papers, 58 citations indexed

About

Douglas Cannie is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Douglas Cannie has authored 13 papers receiving a total of 58 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 4 papers in Molecular Biology and 2 papers in Oncology. Recurrent topics in Douglas Cannie's work include Atrial Fibrillation Management and Outcomes (5 papers), Cardiomyopathy and Myosin Studies (5 papers) and Viral Infections and Immunology Research (3 papers). Douglas Cannie is often cited by papers focused on Atrial Fibrillation Management and Outcomes (5 papers), Cardiomyopathy and Myosin Studies (5 papers) and Viral Infections and Immunology Research (3 papers). Douglas Cannie collaborates with scholars based in United Kingdom, Italy and Switzerland. Douglas Cannie's co-authors include Riyaz A. Kaba, Perry Elliott, Juan Pablo Kaski, Petros Syrris, Emanuele Monda, Giuseppe Limongelli, Constantinos O’Mahony, Athanasios Bakalakos, Mohammed Akhtar and Kush Patel and has published in prestigious journals such as European Heart Journal, JACC Heart Failure and Pacing and Clinical Electrophysiology.

In The Last Decade

Douglas Cannie

13 papers receiving 56 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Cannie United Kingdom	4	47	9	5	4	4	13	58
Priit Pauklin Estonia	3	36 0.8×	9 1.0×	10 2.0×	3 0.8×	4 1.0×	5	50
María Esther Guisado Espartero Spain	3	51 1.1×	10 1.1×	5 1.0×	5 1.3×	4 1.0×	4	61
Ajar Koçak Türkiye	4	16 0.3×	13 1.4×	5 1.0×	2 0.5×	3 0.8×	13	29
Hannes Melnyk Germany	4	27 0.6×	14 1.6×	12 2.4×	2 0.5×	6 1.5×	6	45
Staniel Ortmans France	4	34 0.7×	3 0.3×	9 1.8×	4 1.0×	4 1.0×	7	40
Nerma Resić Bosnia and Herzegovina	3	21 0.4×	6 0.7×	3 0.6×	4 1.0×	1 0.3×	7	32
Sasko Kedev Serbia	3	25 0.5×	6 0.7×	13 2.6×	3 0.8×	4 1.0×	6	36
Lijun Kuang China	5	19 0.4×	4 0.4×	3 0.6×	4 1.0×	4 1.0×	7	40
S. N. Тereschenko Russia	5	44 0.9×	8 0.9×	10 2.0×	1 0.3×	14 3.5×	20	55
José L. Morales Mexico	6	69 1.5×	8 0.9×	5 1.0×	5 1.3×	12 3.0×	14	86

Countries citing papers authored by Douglas Cannie

Since Specialization

Citations

This map shows the geographic impact of Douglas Cannie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Cannie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Cannie more than expected).

Fields of papers citing papers by Douglas Cannie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Cannie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Cannie. The network helps show where Douglas Cannie may publish in the future.

Co-authorship network of co-authors of Douglas Cannie

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Cannie. A scholar is included among the top collaborators of Douglas Cannie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Cannie. Douglas Cannie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Ministrini, Stefano, Alexander Akhmedov, Yustina M. Puspitasari, et al.. (2024). Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients. Vascular Pharmacology. 156. 107411–107411. 2 indexed citations

Monda, Emanuele, Athanasios Bakalakos, Douglas Cannie, et al.. (2024). Prevalence of pathogenic variants in cardiomyopathy-associated genes in acute myocarditis: a systematic review and meta-analysis. European Heart Journal. 45(Supplement_1). 1 indexed citations

Monda, Emanuele, Athanasios Bakalakos, Douglas Cannie, et al.. (2024). Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Acute Myocarditis. JACC Heart Failure. 12(6). 1101–1111. 22 indexed citations

Cannie, Douglas, Kush Patel, Alexandros Protonotarios, et al.. (2024). Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block. Open Heart. 11(1). e002606–e002606. 3 indexed citations

Cannie, Douglas, Kush Patel, Leon Menezes, et al.. (2023). 9 Prevalence of transthyretin cardiac amyloidosis in patients with high degree AV block. A11–A12. 1 indexed citations

Cannie, Douglas & Perry Elliott. (2021). The genetics of left ventricular noncompaction. Current Opinion in Cardiology. 36(3). 301–308. 3 indexed citations

Protonotarios, Alexandros, Douglas Cannie, Mohammed Akhtar, et al.. (2020). Exploring the phenotypic spectrum of desmoplakin cardiomyopathy. European Heart Journal. 41(Supplement_2). 1 indexed citations

Cannie, Douglas, Mohammed Akhtar, & Perry Elliott. (2019). Hidden in Heart Failure. European Cardiology Review. 14(2). 89–96. 4 indexed citations

Cannie, Douglas, Adam Graham, Anthony W. Chow, et al.. (2018). Anticoagulation and the risk of complications in ventricular tachycardia and premature ventricular complex ablation. Pacing and Clinical Electrophysiology. 41(11). 1454–1460. 2 indexed citations

10.

Cannie, Douglas, Andrew T. Cox, Iain Parsons, et al.. (2015). 80 Should Military Recruits be Screened with a 12-lead ECG in addition to History and Physical Examination?. A44.1–A44. 1 indexed citations

11.

Kaba, Riyaz A., et al.. (2014). RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation. Global Cardiology Science and Practice. 2014(2). 26–26. 9 indexed citations

12.

Kaba, Riyaz A., et al.. (2014). Response to ‘Lack of reversibility for NOACs’. Global Cardiology Science and Practice. 2014(1). 2–2. 3 indexed citations

13.

Kaba, Riyaz A., et al.. (2013). ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. Global Cardiology Science and Practice. 2013(4). 41–41. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact